Active Biotech AB (publ)

Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. Show More...

  • Website https://www.activebiotech.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.03 EUR
  • Last Updated 29-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share SEK -2.36 -0.96 -1.77 -1.96 -2.11 -1.6 -0.49 -0.89 -0.27 -0.24 -0.25
    Dividends SEK
    Payout Ratio % *
    Shares Mil 94.0 98.0 99.0 108.0 110.0 121.0 121.0 122.0 137.0 145.0 145.0
    Book Value Per Share * EUR 0.25 0.65 0.39 0.5 0.25 0.23 0.11 0.11 0.06 0.04 0.03
    Free Cash Flow Per Share * EUR -0.23 -0.03 -0.25 -0.27 -0.16 -0.22 -0.07 -0.04 -0.03 -0.02
    Return on Assets % -44.14 -13.89 -22.51 -28.96 -31.07 -33.03 -13.82 -30.36 -12.17 -18.48 -20.77
    Financial Leverage (Average) 2.77 1.71 2.05 1.89 1.78 2.49 2.26 3.91 3.44 1.24 1.24
    Return on Equity % -119.37 -27.66 -41.58 -56.91 -57.11 -66.06 -32.81 -83.61 -44.54 -48.18 -58.51
    Return on Invested Capital % -49.07 -15.57 -25.54 -33.61 -35.25 -36.25 -13.14 -29.62 -10.31 -18.43 -58.51
    Interest Coverage -34.84 -6.08 -16.97 -23.36 -29.58 -25.9 -7.67 -14.39 -4.29 -16.63
    Current Ratio 1.81 3.91 2.46 2.8 3.6 2.27 3.63 1.34 1.4 5.71 5.83
    Quick Ratio 1.68 3.84 2.42 2.77 3.54 2.18 3.38 0.11 0.12 5.48 5.83
    Debt/Equity 1.33 0.47 0.67 0.55 0.55 1.2 1.13 0.04